



## ARCHIVIO ISTITUZIONALE DELLA RICERCA

### Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

*Published Version:*

Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study / Casadei-Gardini A; Marisi G; Dadduzio V; Gramantieri L; Faloppi L; Ulivi P; Foschi F G; Tamburini E; Vivaldi C; Rizzato M D; Ielasi L; Canale M; Conti F; Rudnas B; Fornaro L; Silvestris N; Silletta M; Cardellino G G; Lonardi S; Fornari F; Orsi G; Rovesti G; Zagonel V; Cascinu C; Scartozzi M. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - ELETTRONICO. - 26:17(2020), pp. 4485-4493. [10.1158/1078-0432.CCR-19-3897]

This version is available at: <https://hdl.handle.net/11585/851049> since: 2023-11-17

*Published:*

DOI: <http://doi.org/10.1158/1078-0432.CCR-19-3897>

*Terms of use:*

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

(Article begins on next page)

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).  
When citing, please refer to the published version.

This is the final peer-reviewed accepted manuscript of:

Casadei-Gardini A, Marisi G, Dadduzio V, Gramantieri L, Faloppi L, Ulivi P, et al. Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. Clinical Cancer Research. 2020;26:4485–93.

The final published version is available online at:

<https://dx.doi.org/10.1158/1078-0432.CCR-19-3897>

#### Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

*This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>)*

***When citing, please refer to the published version.***

Association of *NOS3* and *ANGPT2* gene polymorphisms with survival in patients with  
hepatocellular carcinoma receiving sorafenib: results of the multicenter prospective INNOVATE  
study

Andrea Casadei-Gardini<sup>1</sup>, Giorgia Marisi<sup>2</sup>, Vincenzo Dadduzio<sup>3</sup>, Laura Gramantieri<sup>4</sup>, Luca Faloppi<sup>5</sup>, Paola Ulivi<sup>2</sup>, Francesco Giuseppe Foschi<sup>6</sup>, Emiliano Tamburini<sup>7</sup>, Caterina Vivaldi<sup>8</sup>, Mario Domenico Rizzato<sup>3-9</sup>, Luca Ielasi<sup>4</sup>, Matteo Canale<sup>2</sup>, Fabio Conti<sup>6</sup>, Britt Rudnas<sup>10</sup>, Lorenzo Fornaro<sup>11</sup>, Nicola Silvestris<sup>12-13</sup>, Marianna Silletta<sup>14</sup>, Giovanni Gerardo Cardellino<sup>15</sup>, Sara Lonardi<sup>3</sup>, Francesca Fornari<sup>4</sup>, Giulia Orsi<sup>1</sup>, Giulia Rovesti<sup>1</sup>, Vittorina Zagonel<sup>3</sup>, Stefano Cascinu<sup>16</sup>, Mario Scartozzi<sup>17</sup>

<sup>1</sup> Department of Oncology and Hematology, Division of Oncology, University Hospital  
Modena, Modena, Italy

<sup>2</sup> Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)  
IRCCS, Meldola, Italy

<sup>3</sup> Medical Oncology Unit 1, Istituto Oncologico Veneto IRCCS, Padova, Italy

<sup>4</sup> Center for Applied Biomedical Research, St. Orsola-Malpighi University Hospital, Bologna, Italy

<sup>5</sup> Department of Oncology, Macerata Hospital, Macerata, Italy

<sup>6</sup> Department of Internal Medicine, Degli Infermi Hospital, Faenza, Italy

<sup>7</sup> Department of Medical Oncology, Card. G. Panico Hospital of Tricase, Tricase, Italy

<sup>8</sup> Department of Translational Research and New Technologies in Medicine and Surgery,  
University of Pisa, Pisa, Italy

<sup>9</sup> Unit of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy

<sup>10</sup> Unit of Biostatistics and Clinical Trials, Istituto scientifico Romagnolo per lo studio e la cura dei Tumori (IRST) IRCCS, Meldola, Italy

<sup>11</sup> Division of Medical Oncology, Pisa University Hospital, Via Roma 67, 56126 Pisa, Italy

<sup>12</sup> Department of Biomedical Sciences and Human Oncology, university of Bari Aldo Moro, 70214 Bari, Italy

<sup>13</sup> MedicalOncology Unit-IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy

<sup>14</sup> MedicalOncology, Università Campus Bio-Medico di Roma, Roma, Italy

<sup>15</sup> University Hospital “S. Maria della Misericordia”, Udine

<sup>16</sup> Department of Oncology, Università Vita-Salute, San Raffaele Hospital IRCCS, Milan, Italy

<sup>17</sup> Medical Oncology, University Hospital of Cagliari, Cagliari, Italy

#### Collaborators:

Giovanni Luca Frassinetti, Martina Valgiusti: Department of MedicalOncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Flavia Pagan; Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Antonella Argentiero, Oronzo Brunetti: MedicalOncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II" of Bari, Bari, Italy.

Daniele Santini: Department of Oncology, Campus Bio-Medico University, via Alvaro del Portillo 200, 00128 Rome, Italy.

Gianluca Masi, Irene Pecora, Silvia Catanese, Francesca Salani: Division of MedicalOncology, Pisa University Hospital, Pisa, Italy.

**Running title:** Polymorphisms in HCC patients treated with sorafenib

**Corresponding Author:** Dr. Giorgia Marisi, Biosciences Laboratory, Istituto Scientifico

Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy; phone: +39

0543739232; e-mail: [giorgia.marisi@irst.emr.it](mailto:giorgia.marisi@irst.emr.it)

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were reported.

## Abstract

**Purpose:**After 10 years of clinical practice and research studies, there are still no validated prognostic or predictive factors of response to sorafenib for hepatocellular carcinoma (HCC). On the basis of the results of our two retrospective studies, we designed the multicenter INNOVATE study with the aim to validate the role of *NOS3* and *ANGPT2* polymorphisms in HCC patients treated with sorafenib [NCT02786342].

**Experimental Design:**This prospective multicenter study was conducted at 10 centres in Italy. All eligible patients received a continuous oral treatment with 400 mg of sorafenib twice daily. Genotyping analysis was performed for *NOS3* (rs2070744) and *ANGPT2* SNPs (rs55633437). The primary outcome was progression free survival (PFS), while secondary outcomes included overall survival (OS) and disease-control rate (DCR).

**Results:**165 patients were enrolled between March 2016 and June 2018. *NOS3* rs2070744 CC/CT genotypes were significantly associated with a higher median PFS (5.9 vs 2.4 months, HR 0.43,  $p=0.0007$ ) and OS (15.7 vs 8.6 months, HR 0.38,  $p<0.0001$ ) compared to TT genotype. There was no statistically significant association between *ANGPT2* rs55633437 TT/GT genotypes and PFS (2.4 vs 5.7 months, HR 1.93,  $p=0.0833$ ) and OS (15.1 vs 13.0 months, HR 2.68,  $p=0.55$ ) when compared to the other genotype. Following adjustment for clinical covariates, multivariate analysis confirmed *NOS3* as an independent prognostic factor for PFS (HR 0.50,  $p=0.0128$ ) and OS (HR 0.29,  $p=0.0041$ ).

**Conclusions:**The INNOVATE study met the primary endpoint, confirming that advanced HCC patients with *NOS3* rs2070744 CC/CT genotypes had a better prognosis with respect to TT genotype patients.

**Keywords:** Prognostic factor, Advanced hepatocellular carcinoma, biomarkers, regorafenib, second line, eNOS

### **Translational relevance**

A significant proportion of HCC patients treated with sorafenib are experiencing difficult-to-treat and quality of life impairing side-effects, without any clinical benefit. In this scenario, clinical or biological predictive factors, able to identify up-front responding and refractory patients, would represent an important clinical asset for both research and patient stratification in clinical practice.

Unfortunately, after more than 10 years of clinical and translational research, still there are no validated biomarkers helping physicians in the decision-making process useful in maximizing results, sparing unnecessary toxicities and possibly guiding treatment selection.

This study confirms that *NOS3* rs2070744 CC/CT genotypes are capable to identify sorafenib-treated patients with longer survival. *NOS3* genotyping analysis is a simple analysis that allows us to better stratify patients in future randomized studies.

## Introduction

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and it has become the 5th most common malignancy worldwide and it is the 3<sup>rd</sup> leading cause of cancer-related death. The estimated incidence of new cases is about 500,000-1000,000 globally, with 600,000 deaths per year.(1)

Following the positive results of two phase III trials, the SHARP study in 2007(2) and the Asia Pacific study in 2008,(3) sorafenib has been approved by regulatory authorities as the standard of care for the first-line treatment of HCC patients with advanced stage of disease, and for patients with intermediate stages of disease that are refractory to loco-regional therapy, according to Barcelona Clinic Liver Cancer (BCLC).

However, a significant proportion of HCC patients treated with sorafenib are experiencing difficulty to treat and quality of life impairing side-effects, without receiving any clinical benefit. In this scenario, clinical or biological predictive factors able to identify up-front responding and refractory patients might represent an important clinical asset for both research and daily clinical practice. In addition, new therapeutic options are already or will be soon available in this setting, making the selection of the appropriate treatment for the appropriate patient more crucial than ever.

Unfortunately, after more than 10 years of clinical and translational research, there are still no validated biomarkers helping physicians in the decision-making process with the aim of maximizing results, sparing unnecessary toxicities and possibly guiding treatment selection.(4)

To date, the only relevant and available findings in this area come from subset and pooled analysis of the 2 main trials,(2, 3) whereas validation prospective trials are lacking.

Only a few studies identified possible prognostic or predictive markers for sorafenib in HCC patients. In the SHARP trial, Llovet and co-workers found that low VEGF-A and Ang-2 plasma baseline concentrations predicted survival in patients with advanced HCC.(5)



Moreover, a recent study of Harding and co-workers demonstrated that advanced HCC patients harboring PI3K-mTOR pathway alterations had significantly worse outcomes under sorafenib treatment.(6)

In our ePHAS retrospective study, a training cohort of 41 HCC patients and a validation cohort of 87 patients receiving sorafenib were analysed to evaluate the prognostic role of the endothelial nitric oxide synthase (eNOS), also known as nitric oxide synthase 3 (*NOS3*) polymorphisms(7). At univariate and multivariate analyses, patients with *NOS3*rs2070744CC/CT genotypes showed a higher median overall survival (OS) compared to patients with *NOS3*rs2070744 TT genotype.(7) In our second retrospective study patients with *ANGPT2* rs55633437 GG genotype showed a significantly higher median OS and progression free survival (PFS) than patients carrying *ANGPT2* rs55633437 TT/GT genotypes (8)

On the basis of these preliminary results, INNOVATE study has been designed with the aim of validating through a multicentre prospective study the potential role of *NOS3* and *ANGPT2* polymorphisms in patients with HCC treated with sorafenib [NCT02786342].(9)

## **Patients and Methods**

### **Patients**

The study population consists of 165 patients with advanced-stage (BCLC C) HCC and patients with intermediate (BCLC B) HCC not eligible for loco-regional treatments (surgical resection, percutaneous ablation, TACE) or liver transplantation(9). The eligibility criteria also included an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less, Child–Pugh liver function class A or B7 with bilirubin <2, a life expectancy of 12 weeks or more, adequate hematologic function (platelet count,  $\geq 60 \times 10^9$  per liter; haemoglobin  $\geq 8.5$  gr/dl, adequate hepatic function (albumin,  $\geq 2.8$  g/dl; total bilirubin,  $\leq 2$  mg per deciliter; and alanine aminotransferase and aspartate aminotransferase,  $\leq 5$  times the upper limit of the normal range), and adequate renal function (serum creatinine,  $\leq 1.5$  times the upper limit of the normal range).

Patients were required to have at least one untreated target lesion that could be measured in one dimension, according to the modified Response Evaluation Criteria in Solid Tumours (mRECIST) assessed at each centre. Patients were excluded if they previously received molecular targeted therapies or any other systemic treatment. All patients provided written informed consent before the enrolment in the study. The study was approved by ethics committee at each centre and complied with the provisions of the Good Clinical Practice guidelines and the Declaration of Helsinki and local laws.

### **Study Design**

This prospective multicenter phase IV study was conducted at 10 Italian centers. All eligible patients received a continuous oral treatment with 400 mg of sorafenib (consisting of two 200-mg tablets) twice daily. For each patient, a blood sample was collected at baseline (the same day of sorafenib initiation).

Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) were permitted for drug-related adverse effects (physician's choice). Adverse events were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 and seriousness of adverse events was recorded.

Treatment continued until the occurrence of radiologic progression, as defined by mRECIST, symptomatic progression, unacceptable adverse events or death.

The schedule of study procedures was reported in Supplementary Table S1.

Trial registration: Clinical trial NCT02786342, version 1.1.(9)

### **DNA isolation and genotyping analysis**

Peripheral blood samples (3mL) collected in EDTA-tubes were used for polymorphism analysis. Genomic DNA was extracted from 200ul of whole blood using QIAamp DNA

Minikit(Qiagen SPA, Milan, Italy) following the manufacturer's protocol. DNA quantity and quality were assessed by Nanodrop 1000 (Celbio, Milan, Italy).

Genotyping analysis was performed for *NOS3* (rs2070744) and *ANGPT2* SNPs (rs55633437).

*NOS3* rs2070744 was analysed by Real-Time Polymerase chain reaction (PCR) using a TaqMan SNP Genotyping assay (Assay ID C\_15903863\_10, Applied Biosystems, Foster City, CA, USA). Genotypes were assessed by a 7500 Real-Time PCR System (Applied Biosystems) using a 7500 Software version 2.3 (Applied Biosystems). PCRs were performed starting from 20 ng of genomic DNA.

*ANGPT2* rs55633437 was instead determined by a standard PCR and direct sequencing analysis on an ABI 3130 Genetic Analyzer (Applied Biosystems). PCRs were performed starting from 50 ng of genomic DNA. The primer sequences and PCR conditions are reported in our previous study.(8)

All samples were analysed at the same institution (Biosciences Laboratory at IRST, Meldola, Italy) and all genotyping analysis were performed at the end of patient recruitment. Physicians treating were blinded to polymorphisms results and laboratory personnel were blinded to patient clinical outcome.

## **Outcomes and Assessments**

The primary outcome of the study was PFS. PFS was defined as the time from entry into the study until the first observation of documented disease progression or death due to any cause, whichever occurred first. Patients without tumour progression at the time of analysis were censored at the time of their last follow-up.

Secondary outcomes included OS and disease-control rate (DCR). OS was defined as the observed length of life from study entry to death for any cause or to last contact date of patients lost to follow up. DCR was defined as the percentage of patients who had a best-response rating of complete

response (CR), partial response (PR), or stable disease (SD) (according to mRECIST(10)). Safety was assessed in all patients receiving at least one dose of study drug.

Tumour evaluations were performed at screening, every 8 weeks during treatment (within 10 days before the end of each cycle) and at the end of treatment by abdominal and thorax computed tomography.

### **Statistical analysis**

The primary outcome was assessed according to the intention-to-treat population. On the basis of the results from our previous studies, we assumed a 0.50 prevalence of the polymorphisms to be validated. Through a sample size of 80 patients for each group is 80 (160 total sample size), an exponential maximum likelihood test of equality of survival curves with a 0.05 two-sided significance level reaches 90% power to detect the difference between a group 1 exponential parameter,  $\lambda_1$  of 0.1155 (median PFS of 6 months) and a group 2 exponential parameter,  $\lambda_2$  of 0.198 (median PFS of 3.5 months, a constant hazard ratio of 0.58). Patient enrolment period was about 24 months. We considered a follow-up period of at least 12 months for each patient.(9)

OS and 95% Confidence Interval (95 % CI) were estimated with Kaplan-Meier product-limit method. Further analyses of PFS/OS were performed using a multivariable Cox model, and we inserted all positive parameters in univariate analysis after Bonferroni correction.

All tests were two-sided at a significance level of 0.05; no interim analyses were planned.

MedCalc package (MedCalc® version 16.8.4) was used for statistical analysis.

### **Results**

As shown in Fig.1, 182 patients had been screened between March, 2<sup>nd</sup>2016 and June, 27<sup>th</sup>2018.

Seventeen patients did not satisfy the inclusion criteria and were considered as screening failure. 165 patients were enrolled in the study ("intention-to-treat" population) and were treated with sorafenib.

The main characteristics of the 165 patients enrolled in the study are summarized in Table 1. Child-Pugh class-A was the most represented (88.5%), 65.5% had a BCLC-C stage disease, and 20.0% of

patients had  $\alpha$ -fetoprotein (AFP) level  $\geq 400$  ng/ml. The most common underlying aetiology was hepatitis infections from C virus (37.6%). In terms of main characteristics, no differences were found between *NOS3* rs2070744 CC/CT and *NOS3* rs2070744TT (Supplementary Table S2). At the time of database lock in February 2019, after a median follow-up time of 25.9 months, 127 patients had progressed and 114 had died. Median OS was 13.1 months (95% CI 10.4-15.7) and median PFS was 5.2 months (95% CI 4.5-6.5) (Supplementary Fig.S1).

Best response to sorafenib treatment were CR in 1% of patients, PR in 8.6% of patients, SD in 25.8% of patients and PD in 64.6% of patients, while the DCR was 35.4%. Twenty-five percent of patients discontinued sorafenib treatment for intolerance and 46.1% of patients received other treatments after sorafenib progression/intolerance.

Genotype frequencies of *NOS3* and *ANGPT2* polymorphisms are shown in Supplementary Table S3 and all genotype frequencies followed the Hardy-Weinberg equilibrium.

At univariate analysis, *NOS3* rs2070744 CC/CT genotypes were significantly associated with a higher median PFS (5.9 vs 2.4 months, HR 0.43, 95% CI 0.26-0.70,  $p=0.0007$ ) and OS (15.7 vs 8.6 months, HR 0.38, 95% CI 0.24-0.60,  $p<0.0001$ ) compared to the other genotype (Fig. 2). After Bonferroni correction, these results remained statistically significant.

At univariate analysis, there was no statistically significant association of *ANGPT2* rs55633437 GG genotype with PFS (5.7 vs 2.4 months, HR 0.52, 95% CI 0.25-1.10,  $p=0.0833$ ) and OS (13.0 vs 15.1 months, HR 1.20, 95% CI 0.65-2.20,  $p=0.55$ ) when compared to other genotypes (Fig. 2).

Regarding baseline patient characteristics, univariate analysis identified Portal Vein Thrombosis Yes (vs No), BCLC C (vs B), child pugh B (vs A), LDH > normal value (vs < normal value), albumin < 35 g/L (vs > 35), AST > normal value (vs < normal value) and a decrease of sodium and platelets for OS and PLR for PFS (Table 2; Supplementary Fig.S2).

No significant association was found between the main clinical-pathologic characteristics of patients and *NOS3* polymorphisms.

Following adjustment for clinical covariates with Bonferroni correction (PLR and *NOS3* for PFS; Portal Vein Thrombosis, BCLC and *NOS3* for OS), multivariate analysis confirmed *NOS3* as an independent prognostic factor for PFS (HR 0.50, 95% CI 0.29–0.86,  $p=0.0123$ ) and OS (HR 0.44, 95% CI 0.29–0.68,  $p=0.0002$ ; Supplementary Table S4).

### ***NOS3* and *ANGPT2* genotypes and objective response**

Regarding *NOS3* polymorphisms, no differences were found between *NOS3* rs2070744 TT and *NOS3* rs2070744 CT/CC genotypes in terms of DCR (34.6% vs. 35.8%;  $p=1.00$ ).

Regarding *ANGPT2*, no differences were found between *ANGPT2* rs55633437 GG and *ANGPT2* rs55633437 TT/GT genotypes in terms of DCR (35.0% vs. 38.4%;  $p=1.00$ ).

### ***NOS3* and *ANGPT2* genotypes and toxicities**

Adverse Events (AEs) of any grade were reported in 83.0% of patients (Grade 1: 9.6%; Grade 2: 38.2%; Grade 3: 35.1%) (Supplementary Table S5).

A trend for better PFS and OS was found in patients that experienced any toxicity compared to patients without toxicity (OS: 15.4 months vs 8.1 months, HR 0.66, 95% CI 0.41-1.06,  $p=0.0869$ ; PFS: 4.5 months vs. 3.7 months, HR 0.56, 95% CI 0.30-1.05,  $p=0.0733$ ).

Maximum toxicity in grade 0-1 versus > 1 highlighted a trend for OS improvement (15.4 months vs. 10.3 months, HR 0.68, 95% CI 0.44-1.05,  $p=0.0874$ ) and a better PFS in patients with toxicity of grade >1 (6.7 months vs. 3.7 months, HR 0.40, 95% CI 0.22-0.72,  $p=0.0027$ ).

AST toxicity grade 0-1 versus >1 was correlated with better OS (13.3 months vs 9.2 months, HR 0.38, 95% CI 0.16-0.93,  $p=0.0343$ ) and diarrhoea grade >1 for better PFS (8.2 months vs. 3.1 months, HR 0.66, 95% CI 0.45-0.96,  $p=0.0335$ ). No other correlations were found (Supplementary Table S6).

No significant associations were observed between *NOS3* polymorphism and toxicity (any toxicity  $p=1.00$ ; elevated ALT  $p=0.72$ ; elevated AST  $p=0.29$ ; elevated bilirubin  $p=1.00$ ; diarrhoea  $p=1.00$ ; hand-foot skin toxicity  $p=0.83$ ; asthenia  $p=0.30$ ; hypertension  $p=0.64$ ).

Evaluation of blood pressure changes between baseline and different timepoints in patients with *NOS3*rs2070744CC/CT genotype (14°, 28°, 60° days) highlighted a more significant increase of diastolic pressure at 28 days respect to patients with *NOS3*rs2070744 TT genotype (Supplementary Fig.S3).

*ANGPT2* rs55633437 GT/TT genotypes were associated with AST toxicity (100% vs 25.4%,  $p=0.0007$ ), whereas no significant associations were observed for other toxicities (All toxicity  $p=1.00$ ; ALT  $p=0.31$ ; Bilirubin  $p=0.67$ ; Diarrhoea  $p=0.54$ ; hand-foot skin toxicity  $p=0.76$ ; asthenia  $p=0.13$ ; hypertension  $p=1.00$ ).

## **Second line treatment**

Median OS after progression or intolerance to sorafenib was 5.3 months (95% CI 4.3-8.0).

Second line treatment data were available for 89 patients: 46.1% of them received other treatments after sorafenib progression/intolerance (22 patients received metronomic capecitabine, 11 patients regorafenib and 7 patients other treatments).

*NOS3* rs2070744 CC/TC genotypes were significantly associated with a higher median OS considering all second line population (6.7 vs 3.5 months, HR 0.56, 95% CI 0.32-0.95,  $p=0.0343$ , Fig 3A) and a trend was observed in the cohort of patients treated with regorafenib (3.4 vs 9.9 months, HR 0.13, 95% CI 0.01-1.06,  $p=0.057$ ) (Fig 3B). No differences were found in patients treated with capecitabine ( $p=0.90$ ), other treatments ( $p=0.10$ ) and in patient without any treatment ( $p=0.07$ ). Interaction test on *NOS3* polymorphisms and treatment efficacy in regorafenib and no regorafenib treated patients was not statistically significant for OS ( $p=0.9666$ ).

## Discussion

The INNOVATE met its primary endpoint, confirming that advanced HCC patients with *NOS3* rs2070744 CC/CT genotypes have a better prognosis than those with TT genotype. To the best of our knowledge, this is the first time that a prospective cohort study successfully validates a biological prognostic factor in this patient setting. At the time the study was closed, patients with *NOS3* rs2070744 CC/CT genotypes had a median PFS of 5.9 months and median OS of 15.7 months compared to 2.4 months and 8.6 months for those with *NOS3* rs2070744 TT genotype. This difference remained significant after adjustment for baseline factors that were found to influence survival, thus supporting the primary analysis. However, INNOVATE study not confirmed the data on *ANGPT2* rs55633437 TT/GT genotypes. The functional role of this *ANGPT2* polymorphism is not well documented in literature and other factors and SNPs may cooperate with this variant, directly affecting transcription efficiency.

The results from the IMbrave 150 trial (Phase 3 trial of sorafenib versus atezolizumab plus bevacizumab) were recently presented by Cheng et al. (11). It is not possible to compare our study with IMbrave150 study, but an indirect comparison is possible in order to speculate future studies basing on the results of our study. In particular, if we indirectly would analyze the OS of IMbrave 150 trial and OS from our study, we could speculate that, if we select the patients treated with sorafenib with the best prognosis, they may have a prognosis similar to that obtained in the atezolizumab plus bevacizumab arm of IMbrave 150 trial. In fact, 6-month OS was 80% in our study and 85% in the atezolizumab plus bevacizumab arm of the IMbrave 150 trial. It is clear that this observation currently has no clinical value but could be suggestive for generating hypotheses for future studies.

Another unmet clinical need for HCC is the management of patients with intermediate stages of disease, candidate to transarterial chemoembolization (12-14). Several clinical trials have been performed on the combined use of Sorafenib and transarterial



chemoembolization or transarterial chemoembolization alone with negative results. In our opinion, these studies did not reach the primary endpoint because patients were not selected on the basis of prognostic molecular markers. We think that in the future it could be interesting to design studies in this setting by selecting patients on basis of *eNOS* polymorphisms.

In recent years, several drugs demonstrated activity in first- and second-line treatment of patients with advanced HCC(15-18), enhancing therapeutic options and further underlining the importance of patient selection for treatment. In addition, the recently reported negative results for nivolumab in the first-line setting (19)and for pembrolizumab in the second-line setting (20)reinforce the need to better characterize patients undergoing first-line treatments such as sorafenib or lenvatinib, to identify the confounding factors that may explain the poor efficacy of immunotherapy in HCC.To the best of our knowledge, very few studies to date have identified potential markers of response to sorafenib in HCC patients, and none have been validated prospectively (4). Low baseline plasma concentrations of vascular endothelial growth factor A (VEGF-A) and Ang-2 have been associated with better OS in some cases (5, 21), but not in others.

Polymorphism analysis has several advantages over gene or protein expression assays. Most importantly, it can be performed on a peripheral blood sample collected at any time and is not influenced by patient conditions. Secondly, it is a more robust and reproducible analysis because it is directly performed on DNA. It is also less expensive than expression analysis, making it a more welcome option for use in clinical practice.

Previous studies have suggested that DNA variants at the *NOS3* gene quantitatively control eNOS expression. The point variation T>C at nucleotide-786bp of *NOS3* gene has been associated with a significant reduction in *NOS3* gene promoter activity, resulting in lower levels of eNOS mRNA, eNOS protein and a lower enzyme activity, with consequent decreased nitric oxide (NO) production(22-24). We therefore hypothesized an association between low levels of eNOS protein/activity and sorafenib efficacy. With regard to the correlation between sorafenib toxicity and *NOS3* polymorphism, we also found that patients carrying the TT genotype for *NOS3*

rs2070744 showed a significant increase in diastolic blood pressure between baseline and the 28th day of therapy. This finding would seem to be related to eNOS expression. The activation of VEGFR-2 has also been shown to stimulate the production of NO and inhibit endothelin-1 (ET-1), a potent vasoconstrictor(25). In patients treated with sorafenib, VEGFR-2 inhibition may reduce NO, resulting in vasoconstriction and hypertension.

Another interesting data highlighted in this study is the prognostic value of *NOS3* in the second line setting. Obviously, this is a post-hoc analysis with few evaluable patients, but still our study points out the prognostic role of *NOS3* in the overall population and a trend in favour of regorafenib treatment. In light of this finding, future studies should evaluate the sorafenib and regorafenib sequence in patients with *NOS3* rs2070744 CC/CT genotypes.

The main strength of our multicenter study is that the analyses were prospectively performed in order to validate the prognostic role of polymorphisms. Patients were treated by different specialists (oncologist, gastroenterologist and hepatologist) with different expertise in this field and this reinforces the data of our study. The study also has a number of limitations, *e.g.* as our study was carried out on Caucasian patients, it is not possible to know if *NOS3* rs2070744 genotypes are prognostic in an Asian population where hepatitis B is the prevailing aetiology. Another important limitation of our study is the absence of a control arm not receiving sorafenib, making not possible to evaluate the predictive role of *NOS3* polymorphisms and this limits the completeness of results that the study can give. Furthermore, a low number of patients had been enrolled. These limitations reduce the value of the study and we think that a prospective study enrolling larger case series with two arms will be fundamental to definitively understand the role of polymorphism in this patient setting.

Furthermore, we selected PFS as primary endpoint because this endpoint would have not been influenced by subsequent treatment lines in a period of very intensive clinical research with many ongoing clinical trials at many participating Institutions investigating second-line therapy.

The power for OS is 95%, therefore the results obtained for OS are reliable.

In summary, this study shows that *NOS3* rs2070744 CC/CT genotypes are capable to identify patients receiving sorafenib with longer survival. *NOS3* genotyping analysis is a simple analysis that allows us to better stratify patients in future randomized studies.

Before this biomarker can be used in daily clinical practice as a surrogate marker of efficacy or response to sorafenib, further investigations by other authors are needed to confirm our data.

### **Authors' Contribution**

Conception and design: A. Casadei Gardini, G Marisi, M. Scartozzi

Acquisition of data (acquired and managed patients): V. Dadduzio, L. Gramantieri, L. Faloppi, P.

Ulivi, F. G. Foschi, E. Tamburini, C. Vivaldi, M. D. Rizzato, L. Ielasi, M. Canale, F. Conti, B.

Rudnas, L. Fornaro, N. Silvestris, M. Silletta, G.G. Cardellino, S. Lonardi, F. Fornari, G. Orsi, G.

Rovesti, V. Zagonel, S. Cascinu, M. Scartozzi

Analysis and interpretation of data: A. Casadei Gardini, G Marisi, M., L. Faloppi, M. Scartozzi

Writing, review, and/or revision of the manuscript: A. Casadei Gardini, G Marisi, L. Faloppi, M. Scartozzi

Final approval of manuscript: All authors

### **Acknowledgments**

We thank patients and family for participating in this study.

### **References**

1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391(10127):1301-14.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90.

3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2009;10(1):25-34.
4. Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, et al. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? *World J Gastroenterol* 2018;24(36):4152-63.
5. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. *Clin Cancer Res* 2012;18(8):2290-300.
6. Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, et al. Prospective genotyping of hepatocellular carcinoma: Clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. *Clin Cancer Res* 2019;25(7):2116-26.
7. Casadei Gardini A, Marisi G, Faloppi L, Scarpi E, Foschi FG, Iavarone M, et al. eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study. *Oncotarget* 2016;7(19):27988-99.
8. Marisi G, Petracci E, Raimondi F, Faloppi L, Foschi FG, Lauletta G, et al. ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib. *Cancers (Basel)* 2019;11(7):10.3390/cancers11071023.
9. Casadei Gardini A, Faloppi L, Aprile G, Brunetti O, Caparello C, Corbelli J, et al. Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. an INNOVATE study protocol. *Tumori* 2017;tj5000704.
10. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. *Semin Liver Dis* 2010;30(1):52-60.
11. Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Zhu AX, et al. IMbrave150: Efficacy and safety results from a ph 3 study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib

(sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).

ESMO Asia. 2019.

12. Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturges R, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): A randomised placebo-controlled, double-blind, phase 3 trial. *Lancet Gastroenterol Hepatol* 2017;2(8):565-75.

13. Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): A randomised, open label, phase 3 trial. *Lancet Gastroenterol Hepatol* 2018;3(6):424-32.

14. Park JW, Kim YJ, Kim DY, Bae SH, Paik SW, Lee YJ, et al. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. *J Hepatol* 2019;70(4):684-91.

15. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. *Lancet* 2018;391(10126):1163-73.

16. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. *N Engl J Med* 2018;379(1):54-63.

17. Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2019;20(2):282-96.

18. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2017;389(10064):56-66.

19. Yau T, Park JW, Finn RS, Cheng A-, Mathurin P, Edeline J, et al. Nivolumab improved response and showed trend towards improved survival compared to sorafenib in the first-line setting in patients with advanced hepatocellular carcinoma  
. *Annals of Oncology* 2019;Volume 30, Supplement 5.
20. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al.  
Results of KEYNOTE-240: Phase 3 study of pembrolizumab (pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). *Journal of Clinical Oncology* 2019;37:15\_suppl, 4004-4004.
21. Miyahara K, Nouse K, Tomoda T, Kobayashi S, Hagihara H, Kuwaki K, et al. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. *J Gastroenterol Hepatol* 2011;26(11):1604-11.
22. Dosenko VE, Zagoriy VY, Haytovich NV, Gordok OA, Moibenko AA. Allelic polymorphism of endothelial NO-synthase gene and its functional manifestations. *Acta Biochim Pol* 2006;53(2):299-302.
23. Wang J, Dudley D, Wang XL. Haplotype-specific effects on endothelial NO synthase promoter efficiency: Modifiable by cigarette smoking. *Arterioscler Thromb Vasc Biol* 2002;22(5):e1-4.
24. Senthil D, Raveendran M, Shen YH, Utama B, Dudley D, Wang J, et al. Genotype-dependent expression of endothelial nitric oxide synthase (eNOS) and its regulatory proteins in cultured endothelial cells. *DNA Cell Biol* 2005;24(4):218-24.
25. Eechoute K, van der Veldt AA, Oosting S, Kappers MH, Wessels JA, Gelderblom H, et al. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. *Clin Pharmacol Ther* 2012;92(4):503-10.

**Table 1.** Patient characteristics

<b>Clinical and pathologic variables</b>	<b>No (%)</b>
<b>Median age</b>	69 (24-87)
<b>years(range)</b>	
<b>Gender</b>	
Male	139 (88.7)
Female	26 (11.3)
<b>Etiology</b>	
HCV	62 (37.6)
HBV	24 (14.5)
Alcohol	13 (7.9)
NASH	24 (14.5)
Criptogenic	12 (7.3)
hemochromatosis	2 (1.2)
Multifactorial	28 (17.0)
<b>Previous Surgery</b>	
Yes	36 (21.8)
No	129 (78.2)
<b>Previous</b>	
<b>Radiofrequency</b>	
Yes	37 (22.4)
No	128 (77.6)
<b>Previous TACE</b>	
Yes	51 (30.9)
No	114 (69.1)
<b>BCLC stage</b>	
B	57 (34.5)
C	108 (65.5)
<b>Child Pugh</b>	
A	146 (88.5)
B	19 (11.5)
<b>ECOG</b>	
0	104 (63.0)
1	61 (37.0)

<b>Macrovascular invasion</b>	
Yes	61 (37.0)
No	104 (63.0)
<b>Portal hypertension</b>	
Yes	50 (30.3)
No	105 (63.6)
Unknow	10 (6.1)
<b>Extrahepatic disease</b>	
Yes	62 (37.5)
No	103 (62.5)
<b>Portal Vein Thrombosis</b>	
Yes	59 (35.7)
No	106 (64.3)
<b>MELD (range)</b>	
	8 (6-20)
<b>MELD-Na (range)</b>	
	9 (6-19.9)
<b>AFP (range)</b>	
	40.7 (0.6->50.000)
<400	104 (63.0)
≥400	33 (20.0)
Unknow	28 (17.0)
<b>ALBI grade</b>	
1	117 (70.9)
2	18 (29.1)
3	0 (0)

Abbreviations: HCV, hepatitis C virus; HBV, hepatitis B virus; BCLC, Barcelona clinic liver cancer; ECOG, Eastern Cooperative Oncology Group; AFP, alpha-fetoprotein; ALBI, albumin-Bilirubin.



**Table 2.** Univariate analysis of PFS and OS

	PFS		OS	
	HR (95% CI)	P-value	HR (95% CI)	P-value
<i>e</i> NOS-786 (CC/CT vs TT)	0.43 (0.26-0.70)	0.0007	0.38 (0.24-0.60)	<b>&lt;0.0001</b>
ANGPT2 (GG vs GT/TT)	0.52 (0.25-1.10)	0.0833	1.20 (0.65-2.20)	0.55
Child (B vs C)	1.56 (0.72-3.35)	0.2552	2.37 (1.00-5.62)	<b>0.0491</b>
BCLC (C vs B)	1.05 (0.72-1.53)	0.81	1.93 (1.29-2.88)	<b>0.0012</b>
Extra Hepatic Spread (Yes vs No)	1.31 (0.90-1.89)	0.1579	1.35 (0.90-2.00)	0.1420
ECOG (0 vs >0)	0.78 (0.44-1.39)	0.4023	0.81 (0.44-1.48)	0.4918
Age at start of therapy (>70 vs <70)	1.02 (0.71-1.47)	0.9017	1.08 (0.74-1.57)	0.6967
Etiology				
HCV	1		1	
HBV	1.06 (0.61-1.84)		1.65 (0.87-3.15)	
Alcohol	1.09 (0.55-2.17)		0.97 (0.50-1.88)	
Multifactorial	1.50 (0.87-2.58)		1.74 (0.95-3.21)	
Others	1.34 (0.82-2.19)	0.5064	1.63 (0.96-2.79)	0.1227
Portal hypertension (Ref Yes)	1.04 (0.62-1.73)	0.8777	1.76 (0.96-3.20)	0.0656
Portal vein thrombosis (Yes vs No)	0.91 (0.62-1.35)	0.6531	2.04 (1.30-3.18)	<b>0.0017</b>
Macrovascular invasion (Yes vs No)	1.35 (0.79-2.16)	0.3276	1.76 (0.94-2.16)	0.0945
LDH (>NV vs <NV)	1.89 (0.93-3.85)	0.0771	2.21 (1.02-4.80)	<b>0.0429</b>
AFP (continuous variable)	1.00 (1.00-1.00)	0.2415	1.00 (1.00-1.00)	0.1758
AFP (≥400 vs <400)	1.03 (0.66-1.63)	0.8738	1.21 (0.72-2.03)	0.4563
ALBI (2 vs 0-1)	1.08 (0.53-2.20)	0.8198	1.49 (0.67-3.33)	0.3254
Albumin (NV vs <NV)	0.68 (0.43-1.09)	0.1085	0.52 (0.31-0.86)	<b>0.0111</b>
ALT U/L(>NV vs NV)	1.02 (0.62-1.68)	0.9393	1.14 (0.65-1.98)	0.6493
AST U/L(>NV vs NV)	1.54 (0.89-2.65)	0.1175	2.00 (1.05-3.82)	<b>0.0341</b>
Bilirubin mg/dl (continuous variable)	1.04 (0.73-1.48)	0.8154	1.05 (0.74-1.51)	0.7624
Bilirubinmg/dl (> NV vs NV)	1.14 (0.76-1.70)	0.5205	1.06 (0.69-1.64)	0.7737
Creatinine mg/dl (>NV vs NV)	1.30 (0.77-2.19)	0.3279	1.43 (0.82-2.48)	0.1979
Creatinine mg/dl (continuous variable)	1.43 (0.70-2.91)	0.3272	1.52 (0.77-3.00)	0.2242
Hemoglobin g/dl (continuous variable)	0.90 (0.80-1.02)	0.0980	0.93 (0.80-1.08)	0.3561
Alkaline phosphatase (>NV vs NV)	1.10 (0.64-1.87)	0.7356	1.57 (0.86-2.84)	0.1378
Sodium	0.96 (0.88-1.04)	0.3184	0.90 (0.82-0.98)	<b>0.0291</b>
Phosphorus (NV vs <NCV)	1.07 (0.51-2.21)	0.8634	0.40 (0.16-1.06)	0.0671
INR (>NV vs NV)	1.01 (0.68-1.50)	0.9628	1.40 (0.89-2.20)	0.1470
Lymphocyte 10 <sup>9</sup> /L(continuous variable)	0.80 (0.59-1.07)	0.1342	0.88 (0.67-1.16)	0.3805
Neutrophil 10 <sup>9</sup> /L(continuous variable)	1.00 (0.99-1.00)	0.5270	1.00 (0.99-1.03)	0.9287
NLR (>3 vs <3)	1.18 (0.72-1.93)	0.5111	1.09 (0.63-1.90)	0.7444
PLR (>15 vs <15)	2.10 (1.19-3.71)	<b>0.00105</b>	1.28 (0.71-2.30)	0.4036
SII (>360 vs <360)	1.26 (0.77-2.06)	0.3466	1.16 (0.67-2.01)	0.5826
Platelet 10 <sup>9</sup> /L(continuous variable)	1.00 (0.99-1.00)	0.2264	1.00 (1.00-1.00)	<b>0.0150</b>
Platelet 10 <sup>9</sup> /L (>100 vs <100)	1.37 (0.94-2.00)	0.1045	1.26 (0.82-1.93)	0.2910
Calcium (>NV vs NV)	0.50 (0.11-2.25)	0.3671	0.20 (0.02-1.93)	0.1651
BMI(continuous variable)	0.98 (0.94-1.03)	0.5260	1.00 (0.94-1.06)	0.8925
TSH				0.9991

<NV	1.96 (0.69-5.56)		0.98 (0.35-2.75)
NV	1		1
>NV	1.06 (0.45-2.48)	0.2316	0.98 (0.30-3.17)

Abbreviations: Ref, reference; NV normal value; BCLC, Barcelona clinic liver cancer; ECOG, Eastern Cooperative Oncology Group; AFP, alpha-fetoprotein; LDH, lactate dehydrogenase; ALBI, albumin-Bilirubin; INR, International normalized ratio; NLR, neutrophil lymphocyte ratio; PLR, platelet to lymphocyte ratio; SII, systemic immune-inflammation index; BMI, body mass index; TSH, thyroid-stimulating hormone

### Figure Legends:

**Figure 1.** Flow chart of the study population.

**Figure 2:** Kaplan-Meier curves. (A) Progression-free survival (PFS) and (B) overall survival (OS) in relation to *NOS3*rs2070744 polymorphism. (C) PFS and (D) OS in relation to *ANGPT2*rs55633437 polymorphism.

**Figure 3:** Kaplan-Meier curves for *NOS3* polymorphism in second line treatment. (A) All population. (B) Patients treated with regorafenib.

FIGURE 1




FIGURE 2






FIGURE 3



Number at risk							
Group: NOS3 CC+CT							
83	45	22	12	6	2	1	0
Group: NOS3 TT							
29	9	4	3	2	2	0	0



Number at risk							
Group: NOS3 CC+CT							
8	8	7	6	3	2	2	0
Group: NOS3 TT							
3	1	1	1	1	0	0	0